Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Lung Neoplasms 4Glioblastoma 4Uterine Cervical Neoplasms 3Neoplasm Metastasis 3Head and Neck Neoplasms 3Brain Neoplasms 3Rectal Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Lymphoma, B-Cell 2Gliosarcoma 2Esophageal Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Skin Neoplasms 1Sarcoma 1Recurrence 1Pharyngeal Neoplasms 1Pain 1Oropharyngeal Neoplasms 1Oligodendroglioma 1Neuroblastoma 1Neoplasms 1Mouth Neoplasms 1Meningeal Carcinomatosis 1Melanoma 1

Interventions

transplatin 1pembrolizumab 1Radiotherapy 1Radiation Dose Hypofractionation 1Radiation 1Platinum 1Gemcitabine 1Cystectomy 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Infiltrating Bladder Urothelial Carcinoma × Radiation × Clear all
NCT03419130 2018-12-07

Radiation Therapy and Pembrolizumab in Treating Patients With Localized Urothelial Bladder Cancer

University of California, San Francisco

Phase 2 Withdrawn
Genitourinary

Infiltrating Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡